Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) EBITDA Margin (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed EBITDA Margin for 8 consecutive years, with 504.58% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin rose 147206.0% year-over-year to 504.58%, compared with a TTM value of 8381.63% through Sep 2025, down 555258.0%, and an annual FY2024 reading of 20951.0%, down 1751034.0% over the prior year.
  • EBITDA Margin was 504.58% for Q3 2025 at Bicycle Therapeutics, up from 2768.97% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 326.02% in Q4 2023 and bottomed at 2768.97% in Q2 2025.
  • Average EBITDA Margin over 5 years is 780.27%, with a median of 624.78% recorded in 2025.
  • The sharpest move saw EBITDA Margin soared 192044bps in 2022, then tumbled -234032bps in 2025.
  • Year by year, EBITDA Margin stood at 2279.0% in 2021, then skyrocketed by 84bps to 358.56% in 2022, then soared by 191bps to 326.02% in 2023, then plummeted by -31bps to 224.38% in 2024, then crashed by -325bps to 504.58% in 2025.
  • Business Quant data shows EBITDA Margin for BCYC at 504.58% in Q3 2025, 2768.97% in Q2 2025, and 624.78% in Q1 2025.